Data News > Securities Class Action Filed Against Regeneron Pharmaceuticals Inc. (REGN)
- Regeneron Pharmaceuticals Inc. is facing a securities fraud class action after losing $9 billion in market value following its Q3 2024 earnings report.
- The investigation is focused on potential misleading marketing and reimbursement practices related to the company's EYLEA product.
- Shareholders who suffered losses are urged to submit their losses for potential recovery under federal securities laws.
- The class action lawsuit covers individuals and entities that purchased Regeneron securities between November 2, 2023, and October 30, 2024.
- Investors who purchased the company's securities during the Class Period are encouraged to contact the Schall Law Firm before March 10, 2025.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is currently facing a securities fraud class action after experiencing a significant loss of $9 billion in market value following the release of its Q3 2024 earnings report. The company's shares plummeted $84.59 on October 31, 2024, prompting the investigation by Hagens Berman into potential misleading marketing and reimbursement practices related to its EYLEA product, which is used to treat age-related macular degeneration by inhibiting anti-VEGF.
Shareholders who suffered substantial losses as a result of the market decline are being encouraged to submit their losses for potential recovery under the federal securities laws. The class action lawsuit covers individuals and entities that purchased or otherwise acquired Regeneron securities between November 2, 2023, and October 30, 2024, inclusive of these dates. The lawsuit seeks to recover damages against Regeneron Pharmaceuticals, Inc. for alleged violations of the federal securities laws.
Investors who purchased the company's securities during the Class Period are urged to take action with various law firms, including Levi & Korsinsky and the Schall Law Firm, by contacting them before March 10, 2025. These firms are facilitating the submission of losses and are providing information on potential recovery options for affected investors. It is essential for shareholders who believe they have incurred losses as a result of Regeneron's alleged violations to seek advice and explore their legal options.
For more information:
Up/Down Rally Price Distribution Analyst Recommendations Earning Price Impact Analysis Seasonality
Securities Class Action Filed Against Regeneron Pharmaceuticals Inc. (REGN)
By KlickAnalytics Data Insights | January 10, 2025 10:00AM ET
Key Points
- Regeneron Pharmaceuticals Inc. is facing a securities fraud class action after losing $9 billion in market value following its Q3 2024 earnings report.
- The investigation is focused on potential misleading marketing and reimbursement practices related to the company's EYLEA product.
- Shareholders who suffered losses are urged to submit their losses for potential recovery under federal securities laws.
- The class action lawsuit covers individuals and entities that purchased Regeneron securities between November 2, 2023, and October 30, 2024.
- Investors who purchased the company's securities during the Class Period are encouraged to contact the Schall Law Firm before March 10, 2025.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is currently facing a securities fraud class action after experiencing a significant loss of $9 billion in market value following the release of its Q3 2024 earnings report. The company's shares plummeted $84.59 on October 31, 2024, prompting the investigation by Hagens Berman into potential misleading marketing and reimbursement practices related to its EYLEA product, which is used to treat age-related macular degeneration by inhibiting anti-VEGF.
Shareholders who suffered substantial losses as a result of the market decline are being encouraged to submit their losses for potential recovery under the federal securities laws. The class action lawsuit covers individuals and entities that purchased or otherwise acquired Regeneron securities between November 2, 2023, and October 30, 2024, inclusive of these dates. The lawsuit seeks to recover damages against Regeneron Pharmaceuticals, Inc. for alleged violations of the federal securities laws.
Investors who purchased the company's securities during the Class Period are urged to take action with various law firms, including Levi & Korsinsky and the Schall Law Firm, by contacting them before March 10, 2025. These firms are facilitating the submission of losses and are providing information on potential recovery options for affected investors. It is essential for shareholders who believe they have incurred losses as a result of Regeneron's alleged violations to seek advice and explore their legal options.
For more information:
Disclaimer: the above is a summary showing certain market information. KlickAnalytics is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from various resources and more. Communications displaying market prices, data and other information available in this post are meant for purely for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.